Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Hammers on Nivolumab/Ipilimumab Data in RCC

January 7th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses a mature data set regarding nivolumab and ipilimumab in the treatment of patients with renal cell carcinoma.

Dr. Odisho on a Risk Prediction Model in Renal Cell Carcinoma

January 6th 2017

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.

The Times They Are a Changin'

January 5th 2017

As a result of the most recent presidential election, it is a big unknown what the new administration will bring as it relates to the future of healthcare in the US.

Dr. Petrylak on Novel Immunotherapy Research in Bladder Cancer

January 4th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.

Two Landmark Conferences Contribute to Progress in Kidney and Bladder Cancers

January 4th 2017

The tail-end of this year saw 2 annual conferences occurring at the same time: the 2016 Large Urology Group Practice Association annual meeting in Chicago, and the 15th annual International Kidney Cancer Symposium in Miami. Both are covered in this issue’s Conference Highlights section, featuring key stories and landmark research in their respective fields.

Amid Explosion of Novel Agents, Chemo Could Still Have Curative Role in Urothelial Carcinoma

December 15th 2016

Even with 1 FDA approval of an immunotherapeutic agent in urothelial carcinoma—and more expected in the coming months—chemotherapy regimens will continue to play a pivotal part in the treatment of patients with this disease.

After Second-Line RCC Approvals, Focus Shifts to Frontline

December 15th 2016

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma, and researchers are now setting their sights on transforming upfront care.

Additional Research Required for Immunotherapy to Replace Chemo in Upfront Bladder Cancer Care

December 13th 2016

Immunotherapy may be having a moment in the changing landscape of bladder cancer, but expert Gopa Iyer, MD, advises that there is much research to be done before physicians replace chemotherapy with these agents upfront.

FDA Grants Priority Review to Durvalumab in Bladder Cancer

December 10th 2016

The FDA has granted a priority review to a biologics license application for the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Immunotherapy Makes Comeback in RCC, But Challenges Remain

December 6th 2016

Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.

Immunotherapy Rapidly Redefining Treatment in Bladder Cancer

December 6th 2016

Daniel P. Petrylak, MD, sheds light on the emerging roles of both immunotherapy and targeted agents in the treatment of patients with bladder cancer.

Dr. Bajorin on Chemotherapy Approaches in Bladder Cancer

December 6th 2016

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Dr. Lee on Sequencing Therapies for Patients With RCC

December 6th 2016

Chung-Han (Joe) Lee, MD, medical oncologist Memorial Sloan Kettering Cancer Center, discusses sequencing therapies for patients with renal cell carcinoma (RCC).

Sanofi's Halt of BCG Production Worries Bladder Cancer Patients and Urologists

December 1st 2016

Sanofi Pasteur plans to discontinue production of Bacillus Calmette-Guérin for the US market by mid-2017, startling physicians and patients who fear that a shortage of the widely used bladder cancer therapy will develop.

Immunotherapy Combos on Horizon in First-Line RCC

December 1st 2016

Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.

Expert Assesses Rapidly Expanding Therapeutic Options in RCC

December 1st 2016

The treatment landscape of renal cell carcinoma is changing at a remarkably fast pace.

Dr. Iyer on Evolving Treatments in Bladder Cancer

November 30th 2016

Gopa Iyer, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy options for patients with bladder cancer, but mentions how other agents are evolving the landscape. Iyer shared this insight during the 2016 OncLive® State of the Science Summit on Genitourinary Cancers.

Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer

November 30th 2016

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Margulis on Different Approaches to Adjuvant Therapy in RCC

November 30th 2016

Vitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.

TKI Sequencing in RCC Will Bring in New Paradigms, Outcomes

November 27th 2016

In the past decade, the addition of tyrosine kinase inhibitors has had a huge impact on the treatment of renal cell carcinoma in the first- and second-line settings. Currently available agents include sorafenib, sunitinib, pazopanib, axitinib, and the recently-added cabozantinib, and lenvatinib.